DENVER, Dec. 13 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that J. William Freytag, President and
Chief Executive Officer, will review the clinical development program for low
dose enoximone capsules at the Wachovia Securities 10 for '05 Biotechnology
Conference. Results from the Company's two pivotal Phase III trials of
enoximone capsules in chronic heart failure, ESSENTIAL I & II, are expected in
mid-2005.
The presentation will take place at 10:00 a.m. (Eastern) on Thursday,
December 16, 2004. There will be a live webcast of the presentation, which
will be accessible through a link posted on the investor relations section of
the Myogen website at http://investor.myogen.com/. The webcast will be
available for replay on Myogen's website through December 31, 2004.
Myogen currently markets one product (Perfan(R) I.V.) in Europe for the
treatment of acute decompensated heart failure and has three product
candidates in late-stage clinical development: enoximone capsules for the
treatment of chronic heart failure, ambrisentan for the treatment of pulmonary
arterial hypertension and darusentan for the treatment of resistant
hypertension. The Company, in collaboration with Novartis, also conducts a
target and drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure and related
cardiovascular disorders. Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release and the anticipated presentation contain
forward-looking statements that involve significant risks and uncertainties,
including those discussed in this release, those to be discussed in the
presentation and others that can be found in the "Risk Factors" section of
Myogen's Form 10-K for the year ended December 31, 2003 and in Myogen's
periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any
obligation to update any forward-looking statements contained in this document
or the anticipated presentation as a result of new information, future events
or otherwise. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected. If the
Company's product candidates, including enoximone, do not meet the safety or
efficacy endpoints in clinical evaluations, they will not receive regulatory
approval and the Company will not be able to market them. Even if the
Company's product candidates meet the safety and efficacy endpoints,
regulatory authorities may not approve them, or the Company may face
post-approval problems that require the withdrawal of its products from the
market.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
